The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ocriplasmin (Jetrea, Thrombogenics, NV) for the treatment of adults with ...

The European Commission has approved the intravitreal eye injection Jetrea, produced by Novartis eye care subsidiary Alcon, for treating vitreomacular traction in the European Union. The disease, ...

JETREA (ocriplasmin) 2.5mg/mL intravitreal injection by ThromboGenics The FDA has approved Jetrea (ocriplasmin; ThromboGeneics) for the treatment of symptomatic vitreomacular adhesion (VMA), a ...

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has ...

Please provide your email address to receive an email when new articles are posted on . ThromboGenics announced positive topline results from the OASIS study of Jetrea in patients with symptomatic ...

Basel, October 23, 2013 - Alcon, the global leader in eye care, and second largest division of Novartis, is pleased that the National Institute for Health and Care Excellence (NICE) has recommended ...

Novartis' Lucentis is approved for various ocular indications – wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular edema (:DME), visual impairment due to macular ...

ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Denmark and Sweden, the third and fourth European markets where the product is now available. Alcon will roll out the drug ...

BRUSSELS, March 18 (Reuters) - Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second ...

Turns out, selling ThromboGenics wasn't such a good idea. After weighing its options, the Belgian company figures it won't look for a buyer. Instead, it will recruit a U.S. marketing partner for its ...

ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA® is listed in the ...